EGFR and non-small cell lung carcinoma: Epidermal growth factor receptor (EGFR) alterations, including L858R and short insertions/deletions (indels) in exon 19, were identified as the first druggable alterations in NSCLC and proved to be the most robust predictive biomarker for EGFR tyrosine kinase inhibitors (TKIs).5